PRVA241220C32500
- 0.00
- 0.000.00%
Privia Health Newsroom
We Think You Can Look Beyond Privia Health Group's (NASDAQ:PRVA) Lackluster Earnings
Privia Health Group: Strong Performance and Growth Potential Justifies Buy Rating
Stifel Nicolaus Sticks to Its Buy Rating for Privia Health Group (PRVA)
A Quick Look at Today's Ratings for Privia Health(PRVA.US), With a Forecast Between $25 to $29
Privia Health Group, Inc. (PRVA) Q3 2024 Earnings Call Transcript Summary
Privia Health Group, Inc. (PRVA) Q3 2024 Earnings Call Transcript
Privia Health Is Maintained at Equal-Weight by Barclays
Express News | Truist Securities Maintains Buy on Privia Health Gr, Raises Price Target to $27
Privia Health Gr Analyst Ratings
A Quick Look at Today's Ratings for Privia Health(PRVA.US), With a Forecast Between $22 to $28
Privia Health Price Target Raised to $21 From $19 at Barclays
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Privia Health Group (PRVA) and Jazz Pharmaceuticals (JAZZ)
Robust Growth and Strategic Expansion Drive 'Buy' Rating for Privia Health Group
Privia Health Q3 Adjusted EPS, Revenue Increase
Privia Health | 10-Q: Q3 2024 Earnings Report
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cross Country Healthcare (CCRN), CVS Health (CVS) and Privia Health Group (PRVA)
Express News | Privia Health Gr Expects FY24 Revenue at High End of Prior Guidance Range of $1.600-$1.675B Vs. Est. $1.83B
Privia Health | 8-K: Privia Health Reports Third Quarter 2024 Financial Results
Privia Health 3Q EPS 3c >PRVA
Privia Health 3Q Adj EPS 20c >PRVA